Back to results
US 2023/0405019 A1Published application
Adjuvant therapy for use in prostate cancer treatment
AssigneeFund SA
InventorF. M. J. Debruyne
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of prostate cancer treatment, and in particular the field of prostate cancer treatment by Androgen Deprivation Therapy (ADT). The present treatment involves oral administration of an estetrol component in conjunction with ADT.
Claims24
A kit-of-parts comprising:
- (a) a first pharmaceutical composition comprising a GnRH agonist;
- and
- (b) a second pharmaceutical composition adapted for oral administration, comprising 20 to 80 mg of estetrol.
Dependencies are inferred from the claim text.